Farnesyltransferase inhibitors in breast cancer therapy

Grace Dy, Alex A. Adjei

Research output: Contribution to journalArticlepeer-review

10 Scopus citations


Farnesyltransferase inhibitors (FTIs) belong to a group of agents originally designed to prevent membrane attachment of Ras protein by inhibiting a key step in its post-translational processing. It was thus hypothesized that FTIs would curtail the oncogenic ras-mediated proliferative and antiapoptotic signals that are activated in human tumors. Although the Ras protein is mutated in only < 5% of breast cancers, there are multiple aberrant pathways that lead to activation of wild-type ras signaling. Moreover, FTIs have consistently demonstrated efficacy in tumors regardless of their ras mutational status. Thus, the role of other protein targets in mediating the antitumor effect of FTIs is being elucidated. This article reviews current data on the use of FTIs in breast cancer.

Original languageEnglish (US)
Pages (from-to)30-37
Number of pages8
JournalCancer Investigation
Issue numberSUPPL. 2
StatePublished - 2002


  • BMS214662
  • Breast cancer
  • Epidermal growth factor receptor
  • Farnesyltransferase inhibitors
  • R115777
  • Ras
  • SCH66336
  • erb-2 receptor

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Farnesyltransferase inhibitors in breast cancer therapy'. Together they form a unique fingerprint.

Cite this